¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific passive immunity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive sensitization
    ¼öµ¿¹Î°¨È­
  • passive shimming
    ¼öµ¿º¸Á¤
  • passive smoking
    °£Á¢Èí¿¬
  • passive transfer
    ¼öµ¿Àü´Þ
  • passive transport
    ¼öµ¿¿î¹Ý
  • reverse passive anaphylaxis
    ¿ª¼öµ¿¾Æ³ªÇʶô½Ã½º
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antitoxic immunity
    Ç×µ¶¼Ò¸é¿ª
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
  • athreptic immunity
    ¹«¿µ¾ç¸é¿ª
  • acquired immunity
    ÈÄõ¸é¿ª
  • active immunity
    ´Éµ¿¸é¿ª
  • adoptive immunity
    Â÷¿ë¸é¿ª, ÀÔ¾ç¸é¿ª
  • concomitant immunity
    ¼ö¹Ý¸é¿ª
  • cross immunity
    ±³Â÷¸é¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive
    ¼öµ¿-, Çǵ¿-
  • passive sensitization
    ¼öµ¿¹Î°¨
  • passive shimming
    ¼öµ¿º¸Á¤
  • passive smoking
    °£Á¢Èí¿¬
  • passive state
    ¼öµ¿»óÅÂ
  • passive transfer
    ¼öµ¿Àü´Þ
  • passive transport
    ¼öµ¿¿î¹Ý
  • passive aggressive personality
    ¼öµ¿°ø°ÝÀΰÝ
  • passive mobility test
    ¼º´ë°¡µ¿°Ë»ç
  • acquired immunity
    ÈÄõ¸é¿ª
  • active immunity
    ´Éµ¿¸é¿ª
  • adoptive immunity
    ÀÔ¾ç¸é¿ª
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antitoxic immunity
    Ç×µ¶¼Ò¸é¿ª
  • artificial active immunity
    Àΰø´Éµ¿¸é¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen, tumor-specific transplantation
    Á¾¾çƯÀÌ À̽ÄÇ׿ø
  • antigen,tumor-specific transplantation
    Á¾¾ç ƯÀÌÀ̽Ä(ðþåË ÷åì¶ì¹ãÕ)
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive agglutination
    ¼öµ¿ÀÀÁý(¡­ëêó¢). (Á¤½Å)¼öµ¿ÀÇÁ¸¼º(ÀÇ).
  • passive aggressive
    Çǵ¿°ø°Ý¼º, ¼öµ¿°ø°ÝÀû.
  • passive anaphylaxis
    Çǵ¿Àû(ù¬ÔÑîÜ)¾Æ³ªÇʶô½Ã.
  • passive anaphylaxis
    Çǵ¿Àû(ù¬ÔÑîÜ)¾Æ³ªÇʶô½Ã½º.
  • passive carrier
    ¼öµ¿º¸±ÕÀÚ(ËÛËÄËÓË»Ëö).
  • passive congestion
    ¼öµ¿¿ïÇ÷(áôÔÑê¦úì)
  • passive congestion
    ¼öµ¿¿ïÇ÷(áôÔÑê¦úì).
  • passive congestion
    ¼öµ¿¿ïÇ÷(áôÔÑê¦úì)
  • passive cutaneous anaphylaxis
    Çǵ¿Àû ÇǺÎ(ù¬ÔÑîÜù«Ý±)¾Æ³ªÇʶô½Ã½º.
  • passive cutaneous anaphylaxis
    Çǵ¿Àû ÇǺÎ(ù¬ÔÑîÜù«Ý±)¾Æ³ªÇʶô½Ã.
  • passive cutaneous anaphylaxis
    ¼öµ¿ÇǺξƳªÇʶô½Ã½º
  • passive cutaneous anaphylaxis
    Çǵ¿Àû ÇǺÎ(ù¬ÔÑîÜù«Ý±)¾Æ³ªÇʶô½Ã½º.
  • passive dependent
    Çǵ¿ÀÇÁ¸¼º.(Á¤½Å)¼öµ¿ÀÇÁ¸¼º(áôÔÑëîðíàõ)(ÀÇ).
  • passive diffusion
    ¼öµ¿Àû È®»ê(¡­îÜüªß¤).
  • passive edema
    ¼öµ¿ºÎÁ¾(áôÔÑÝ©ðþ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular immunity
    ¼¼Æ÷¸é¿ª(á¬øàØóæ¹)
  • immunity
    ¸é¿ª(Øóæ¹)
  • inherited immunity
    À¯Àü¸é¿ª(ë¶îîØóæ¹)
  • innate immunity
    "ÀÚ¿¬¸é¿ª(í»æÔØóæ¹), ¼±Ãµ¸é¿ª(à»ô¸Øóæ¹)"
  • lysogenic immunity
    ¿ë¿ø¸é¿ª(éÁê«Øóæ¹)
  • native immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • natural immunity
    ÀÚ¿¬¸é¿ª(í»æÔØóæ¹)
  • nonspecific immunity
    ºñƯÀÌ ¸é¿ª(Þª÷åì¶Øóæµ)
  • protective immunity
    º¸È£ ¸é¿ª¼º(ÜÁûÞØóæ¹àõ)
  • superinfection immunity
    Áß°¨¿° ¸é¿ª (ñìÊïæøØóæ¹)
  • transferred immunity
    ÀüÀÌ ¸é¿ª (ï®ì¹Øóæ¹)
  • transplantation immunity
    ÀÌ½Ä ¸é¿ª(ì¹ãÕØóæ¹)
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
  • enzyme-specific electrode
    È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
  • organ specific enzyme
    ±â°üƯÀÌÈ¿¼Ò(Ðïί÷åì¶ý£áÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
immun immune, immunity, immunization
HBsAg/adr hepatitis B surface antigen manifesting group-specific determinant a and subtype-specific determinan...
LSP left sacroposterior [fetal position]; linguistic string project; liver-specific protein; lymphocyte-...
SR sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat...
TS Takayasu syndrome; Tay-Sachs; temperature sensitivity; temperature, skin; temporal stem; tensile str...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PCA Passive Cutaneous Anaphylaxis
PHA Passive Haemagglutination
PHN Passive Heymann nephritis
PCA Passive cutaneous anaphylactic
PHA Passive hemagglutination assays
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • passive-aggressive personality
    ¼öµ¿Àû °ø°Ý¼º ÀΰÝ
  • absolute immunity
    Àý´ë ¸é¿ª
  • active immunity
    ´Éµ¿ ¸é¿ª
    Ç׿ø Àڱؿ¡ ¹ÝÀÀÇÏ¿© »ý»êµÈ Ç×ü³ª ¸é¿ª ¸²ÇÁ°è ¼¼Æ÷ÀÇ Á¸Àç·Î ÀÎÇÑ È¹µæ¸é¿ª. »ç¶÷¿¡ ´ëÇØ¼­ ¹é½ÅÀ̳ª µ¶¼ºÀ¸·Î ¸é¿ªÇÏ´Â °ÍÀ¸·Î ÀÚ½ÅÀÇ ¸öÀ¸·Î ¸é¿ªÀ» ¸¸µé¾î³»¹Ç·Î È¿°ú´Â ¿À·¡ Áö¼ÓµÈ´Ù.
  • adoptive immunity
    ÀÔ¾ç ¸é¿ª
    µ¿Á¾ À̽Ä. ¿¹¸¦ µé¸é ¸¶¿ì½ºÀÇ ÇǺΠÀ̽ÄÀ» Çϸé ÀÌ½Ä ÈÄ 10ÀÏ Á¤µµ¿¡¼­ ÀÌ½ÄÆíÀº Å»¶ôÇÏ°í ¼ÒÀ§ °ÅºÎ Çö»óÀÌ ³ªÅ¸³­´Ù. ÀÌ ¸¶¿ì½º¿¡¼­ ¸²ÇÁ±¸¸¦ ¶¼¼­ ±×°ÍÀ» ¹Ìó¸® µ¿°è ¸¶¿ì½º·Î ÀÌÀÔÇÏ°í ±× µ¿¹°¿¡ ÃÖÃÊÀÇ ÇǺΠÀ̽İú °°Àº ÇǺθ¦ À̽ÄÇØÁÖ¸é ÀÌ °æ¿ìµµ °­ÇÑ °ÅºÎ ¹ÝÀÀÀÌ Àüº¸´Ùµµ »¡¸® ÀϾ¸ç À̽ÄÈÄ 3-4ÀÏ·Î ÀÌ½ÄÆíÀÇ ÆÄ±«°¡ ³ªÅ¸³­´Ù. À̰ÍÀº °ÅºÎ Çö»óÀÌ ¸é¿ª ¹ÝÀÀ¿¡ ÀÇÇØ¼­ ÀϾ´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ÀÌ¿Í °°ÀÌ °¨ÀÛ ¸²ÇÁ±¸¿¡ ÀÇÇØ¼­ ¸é¿ª´ÉÀ» ´Ù¸¥ °³Ã¼·Î Àü´ÞÇÏ´Â °ÍÀ» ¾çÀÚ ¸é¿ªÀ̶ó ÇÑ´Ù.
  • allogenic immunity
    µ¿Á¾ ¸é¿ª
  • antiviral immunity
    Ç×¹ÙÀÌ·¯½º ¸é¿ª
  • cell mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª ÀÛ¿ë, ¼¼Æ÷¼º ¸é¿ª
    Ç׿øÀÌ T Àӯı¸¸¦ ÀÚ±ØÇÏ¸é ¸é¿ª ±Û·ÎºÒ¸°À» ÇÕ¼º ºÐºñÇÏ´Â °ÍÀÌ ¾Æ´Ï°í Àӯı¸ ÀÚ½ÅÀÌ Ç×ü·Î ÀÛ¿ëÇÏ´Â °¨ÀÛ Àӯı¸°¡ µÇ´Â °ÍÀÌ Ã¼¾×¼º ¸é¿ª°úÀÇ Â÷ÀÌ·Î, ü¾×¼º ¸é¿ªÀÌ ÁÖ·Î ±Þ¼º ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀε¥ ºñÇØ¼­ ¼¼Æ÷¼º ¸é¿ªÀº ¸¸¼º ¼¼±Õ¼º Áúȯ, Á¶Á÷ À̽Ä, ¾Ï ¼¼Æ÷, °õÆÎÀÌ Áúȯ, ƯÈ÷ ¹ÙÀÌ·¯½º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±âÀüÀÌ´Ù.
  • cell-mediated immunity
    ¼¼Æ÷ ¸Å°³ ¸é¿ª, ¼¼Æ÷ ¸Å°³¼º ¸é¿ª
  • congenital immunity
    ¼±Ãµ¼º ¸é¿ª
  • histogenous immunity
    Á¶Á÷ ¸é¿ª
  • homologous immunity
    µ¿Á¾ ¸é¿ª
  • immunity deficiency
    ¸é¿ª °áÇÌ
    µ¿ÀǾî=immunodeficiency.
  • inborn immunity
    ¼±Ãµ¼º ¸é¿ª
    °³Ã¼ÀÇ À¯ÀüÀû ¼ÒÁú¿¡ ±âÀÎÇÏ´Â ¸é¿ª.
  • infection immunity
    °¨¿° ¸é¿ª
    ÀÌ¹Ì Ç׿øÀÌ °°°Å³ª °ü·ÃµÈ Ç׿øÀ» °¡Áø ¹Ì»ý¹°¿¡ ÀÇÇÑ ÁúȯÀÌ Á¸ÀçÇϱ⠶§¹®¿¡ Àç°¨¿°¿¡ ´ëÇÏ¿© ÀúÇ×·ÂÀÌ ÀÖ´Â »óÅÂ.
  • local immunity
    ±¹¼Ò ¸é¿ª
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
maternal immunity <epidemiology> Immunity for a neonate provided by IgG antibody generated by a mother and passed across the placenta to the unborn offspring. This provides short lived protection (with a typical half life of 3-6 months) to the neonate. Also known as immunity.
(05 Dec 1998)
relative immunity A modified, not completely effective resistance that results when there is a sort of "fluctuating equilibrium" between the defense mechanisms of the host and the infective agent.
(05 Mar 2000)
cell-mediated immunity <immunology> Immune response that involves effector T lymphocytes and not the production of humoral antibody.
Responsible for allograft rejection, delayed hypersensitivity and in defence against viral infection and intracellular protozoan parasites.
(26 Mar 1998)
cellular immunity <cell biology, immunology> Immune response that involves enhanced activity by phagocytic cells and does not imply lymphocyte involvement. Since the term is easily confused with cell-mediated immunity its use in this sense should be avoided.
(26 Mar 1998)
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
group immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
concomitant immunity The paradoxical immune status in which resistance to reinfection coincides with the persistence of the original infection.
Synonym: concomitant immunity.
(05 Mar 2000)
herd immunity <immunology> Resistance of a group to a pathogen due to immunity of a large proportion of the group to that pathogen.
(09 Oct 1997)
humoral immunity <immunology> A form of immunity whereby B lymphocytes and plasma cells produce antibodies to foreign agents (antigens) and stimulate T lymphocytes to attack them (cellular immunity).
These antibodies also stimulate the release of chemical mediators (for example interferon, complement) which enhance antigen destruction.
(06 Mar 1998)
natural immunity This includes local barriers to infection such as skin, stomach acid, mucous, the cough reflex, enzymes in tears and saliva and skin oils.
(27 Sep 1997)
stress immunity Insusceptibility or resistance to the effects of emotional strain.
(05 Mar 2000)
immunity <immunology> The condition of being immune, the protection against infectious disease conferred either by the immune response generated by immunisation or previous infection or by other nonimmunologic factors.
Origin: L. Immunitas
(13 Oct 1997)
immunity, active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination.
(12 Dec 1998)
immunity, cellular Those manifestations of the immune response which are mediated by antigen-sensitised T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
(12 Dec 1998)
immunity deficiency Inabillity to mount a normal immune response. Immunodeficiency can be due to a genetic disease or acquired as in aids due to HIV.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • passive euthanasia
    ¼Ò±ØÀû ¾È¶ô»ç
  • passive immunization
    ¼öµ¿ ¸é¿ª
  • passive obedience
    Àý´ë º¹Á¾;¹¬Á¾
  • passive resistance
    ¼Ò±ØÀû ÀúÇ×
  • passive resister
    ¼Ò±ØÀû ÀúÇ×ÀÚ
  • passive restraint
    ¼öµ¿Àû ¾ÈÀüÀåÄ¡
  • passive sattelite
    ¼öµ¿ À§¼º
  • passive smoking
    °£Á¢ Èí¿¬
  • passive voice
    ¼öµ¿ÅÂ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á